Добірка наукової літератури з теми "Anti-neutrophil cytoplasm antibody"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Anti-neutrophil cytoplasm antibody".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Anti-neutrophil cytoplasm antibody"
Hewins, Peter, and Caroline Savage. "Anti-neutrophil cytoplasm antibody associated vasculitis." International Journal of Biochemistry & Cell Biology 35, no. 3 (March 2003): 277–82. http://dx.doi.org/10.1016/s1357-2725(02)00094-8.
Повний текст джерелаHolle, J. U. "ANCA („anti-neutrophil cytoplasm antibody“)-assoziierte Vaskulitiden." Zeitschrift für Rheumatologie 72, no. 5 (June 2013): 445–56. http://dx.doi.org/10.1007/s00393-013-1211-0.
Повний текст джерелаNAGASAWA, TOSHIHIKO. "Anti-blood neutrophil cytoplasm antibody (ANCA) and glomerulonephritis." Nihon Naika Gakkai Zasshi 83, no. 12 (1994): 2173–78. http://dx.doi.org/10.2169/naika.83.2173.
Повний текст джерелаSalama, A. D., and A. J. Rees. "Autoantibodies in anti-neutrophil cytoplasm antibody-associated vasculitis." Nephrology Dialysis Transplantation 29, no. 6 (January 23, 2014): 1105–7. http://dx.doi.org/10.1093/ndt/gft526.
Повний текст джерелаFerraro, Alastair J., Basma Hassan, and Caroline O. Savage. "Pathogenic mechanisms of anti-neutrophil cytoplasm antibody-associated vasculitis." Expert Review of Clinical Immunology 3, no. 4 (July 2007): 543–55. http://dx.doi.org/10.1586/1744666x.3.4.543.
Повний текст джерелаSalama, Alan D. "Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis." Kidney International Reports 5, no. 1 (January 2020): 7–12. http://dx.doi.org/10.1016/j.ekir.2019.10.005.
Повний текст джерелаMcAdoo, S. P., C. Densem, A. Salama, and C. D. Pusey. "Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody." Clinical Kidney Journal 4, no. 3 (April 2, 2011): 208–10. http://dx.doi.org/10.1093/ndtplus/sfr030.
Повний текст джерелаYOSHIDA, Masaharu, Motoaki SAITO, and Toshihiko NAGASAWA. "Studies on anti-neutrophil cytoplasm antibody(ANCA) in Wegener's granulomatosis." Nihon Naika Gakkai Zasshi 78, no. 11 (1989): 1581–85. http://dx.doi.org/10.2169/naika.78.1581.
Повний текст джерелаJones, Rachel B. "Rituximab in the Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis." Nephron Clinical Practice 128, no. 3-4 (November 14, 2014): 243–49. http://dx.doi.org/10.1159/000368580.
Повний текст джерелаChapman, Gavin B., Andrew E. Leitch, Rashmi Lahiri, Peter Reid, and Neeraj Dhaun. "Strawberry carina as a presentation of anti-neutrophil cytoplasm antibody–associated vasculitis." Rheumatology 61, no. 3 (October 20, 2021): e59-e61. http://dx.doi.org/10.1093/rheumatology/keab783.
Повний текст джерелаДисертації з теми "Anti-neutrophil cytoplasm antibody"
Pankhurst, Tanya. "Heterogeneity of injury in vasculitis : influence of anti neutrophil cytoplasm antibody IgG subclass and endothelial susceptibility." Thesis, University of Birmingham, 2010. http://etheses.bham.ac.uk//id/eprint/718/.
Повний текст джерелаDurant, Stéphanie. "Etude moléculaire et fonctionnelle de la protéinase 3 du neutrophile, cible des ANCA : implications physiopathologiques dans les vascularites." Paris 6, 2003. http://www.theses.fr/2003PA066526.
Повний текст джерела李瑞山 and Shui-shan Lee. "Anti-neutrophil cytoplasmic antibody: a clinical & experimental study." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1993. http://hub.hku.hk/bib/B31981513.
Повний текст джерелаLee, Shui-shan. "Anti-neutrophil cytoplasmic antibody : a clinical & experimental study /." [Hong Kong : University of Hong Kong], 1993. http://sunzi.lib.hku.hk/hkuto/record.jsp?B13762679.
Повний текст джерелаRajp, Amit. "The immunogenetics of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis." Thesis, University of Birmingham, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273729.
Повний текст джерелаBansi, Devinder Singh. "Immunologyical mechanisms in primary primary sclerosing cholangitis : the role of the anti-neutrophil cytoplasmic antibody." Thesis, University of Southampton, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.242304.
Повний текст джерелаGovender, Ramona. "Anti-neutrophil cytoplasmic antibody (ANCA) testing at Groote Schuur Hospital: Adherence to indications for testing." Master's thesis, Faculty of Health Sciences, 2021. http://hdl.handle.net/11427/33700.
Повний текст джерелаBasu, Neil. "The characterisation and determinants of quality of life in ANCA associated vasculitis." Thesis, University of Aberdeen, 2012. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=189406.
Повний текст джерелаBensalem, Amina. "Pharmacocinétique et relation dose-concentration-effet du rituximab dans la polyartrite rhumatoïde et les vascularités associées aux anticorps anti-cytoplasme des neutrophiles." Thesis, Tours, 2019. http://www.theses.fr/2019TOUR3302.
Повний текст джерелаRituximab is a chimeric IgG1 monoclonal antibody (mAb) that targets CD20, a protein on the surface of most B lymphocytes. It is approved as a second line treatment in rheumatoid arthritis (RA) patients, and is used in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There is a large interindividual variability in rituximab pharmacokinetics (PK), and its concentration–response relationship. Rituximab binds to CD20 with high affinity and specificity and form mAb-target complexes which are eliminated by immune system. This elimination is usually described using target-mediated drug disposition (TMDD) models. For rituximab, TMDD was never reported in autoimmune inflammatory diseases, as RA or AAV. This PhD work aimed at studying the variability of PK and cconcentration-response relationship of rituximab using population PK and pharmacokinetic-pharmacodynamic (PK-PD) modeling. This work was done using data from : - 52 RA patients of the rheumatology department of Tours University Hospital, where rituximab concentrations, CD4+ counts (biomarker) and disease activity score in 28 joints (DAS28, clinical response) were measured. - 92 AAV patients included in the RAVE trial (Rituximab for AAV), where rituximab concentrations, antibodies to proteinase 3 (PR3-ANCA), and antibodies to myeloperoxidase (MPO-ANCA) (biomarkers) were measured. In RA patients, rituximab PK was described using a two-compartment model with linear (endogenous) elimination. No target-elimination of rituximab or influence of B-cell count was detected. This may be due to (i) a low amount of target antigen compared to B-cell neoplasia, and/or (ii) insufficiently dense PK data. In AAV patients, nonlinear target-mediated elimination was detected at the beginning of the follow-up. A simplified TMDD model was used, where target was modeled as a latent variable, and irreversible binding to rituximab on its target was assumed. Latent variable may be partly interpreted as the fraction of CD20 (circulating or present at the B-cell membrane) available for rituximab binding. The negligible target-mediated elimination towards the end of the follow-up in RA and AAV may be due to the sustained B-cell depletion after rituximab treatment. Rituximab-induced B cell depletion was shown to alter count and function of other immune cells. However, quantitative relationship between depletion of blood B cells, immune cells, and clinical response in both RA and AAV remain unclear. In addition, this relationship, highly variable among patients, was never quantified using PK-PD modeling. In RA patients, the relationship between rituximab concentrations and CD19+ counts, between CD19+ and CD4+ counts, and between CD4+ counts and DAS28 (clinical activity score in RA) was described using cell lifespan, indirect response and direct Emax models, respectively. This study showed that (i) the amplitude of CD19+ count depletion was not associated with CD4+ decrease or DAS28, and (ii) CD4+ decrease leads to two-fold DAS28 decrease compared to no CD4+ decrease, and (iii) higher rituximab concentrations were related to a better clinical improvement. In AAV patients, the relationship between rituximab concentrations and ANCA levels was described using a semi-mechanistic transit model with negative feedback. This model showed that (i) rituximab-induced decrease of ANCA levels was deep but delayed, and more sustained in patients with MPO-ANCA than in those with PR3-ANCA, and (ii) higher rituximab concentrations were associated with deeper decrease of ANCA levels. Moreover, repeated rituximab courses may improve clinical response to rituximab, and increase the time to disease relapse. Overall, this work was the first to report nonlinear PK of rituximab in autoimmune disease (AAV), and to quantify the complex relationship between rituximab-induced B-cell depletion, CD4+ decrease, and the clinical response
Tieu, Joanna. "Optimising Management in ANCA-Associated Vasculitis." Thesis, 2021. https://hdl.handle.net/2440/135593.
Повний текст джерелаThesis (Ph.D.) -- University of Adelaide, Adelaide Medical School, 2022
Книги з теми "Anti-neutrophil cytoplasm antibody"
Sinico, Renato Alberto, and Loïc Guillevin, eds. Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-02239-6.
Повний текст джерелаRajp, Amit. The immunogenetics of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Birmingham: University of Birmingham, 2002.
Знайти повний текст джерелаGuillevin, Loïc, and Renato Alberto Sinico. Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis. Springer, 2019.
Знайти повний текст джерелаGross, Wolfgang L., and Julia U. Holle. Clinical features of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0131.
Повний текст джерелаFoster, Helen, and Paul A. Brogan, eds. Systemic diseases. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199592630.003.0004.
Повний текст джерелаJayne, David. Treatment of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132.
Повний текст джерелаTombetti, Enrico, and Justin C. Mason. Pathophysiology of vasculitis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755777.003.0017.
Повний текст джерелаЧастини книг з теми "Anti-neutrophil cytoplasm antibody"
Selvakumar, Vijayalakshmi, Thenmozhi Manivel, Ramachandran Chelliah, Kaliyan Barathikannan, Akanksha Tyagi, Xiuqin Chen, Umair Shabbir, et al. "Microorganisms in Pathogenesis and Management of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis." In Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases, 311–39. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4800-8_16.
Повний текст джерелаBoomsma, Maarten M., Coen A. Stegeman, Cees G. M. Kallenberg, and Jan W. Cohen Tervaert. "Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-vessel vasculitis: the role for autoantibody guided and anti-bacterial treatment." In Disease-modifying Therapy in Vasculitides, 181–99. Basel: Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-8235-4_10.
Повний текст джерелаGross, Wolfgang L., and Julia U. Holle. "Clinical features of ANCA-associated vasculitis." In Oxford Textbook of Rheumatology, 1090–102. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0131_update_001.
Повний текст джерелаChung, Sharon, and Paul A. Monach. "Anti-neutrophil Cytoplasmic Antibody–Associated Vasculitis." In Kelley and Firestein's Textbook of Rheumatology, 1541–58. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-323-31696-5.00089-9.
Повний текст джерелаJayne, David. "Treatment of ANCA-associated vasculitis." In Oxford Textbook of Rheumatology, 1103–12. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132_update_001.
Повний текст джерелаVuković Brinar, Ivana, and Matija Matošević. "Complement-Mediated Kidney Disease." In Novel Topics in the Diagnosis, Treatment, and Follow-Up of Nephritis, Nephrotic Syndrome, and Nephrosis [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.108555.
Повний текст джерелаТези доповідей конференцій з теми "Anti-neutrophil cytoplasm antibody"
Chopra, M., and E. Cristan. "Rivaroxaban Induced Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4953.
Повний текст джерелаFidler, L., S. Kandel, J. H. Fisher, S. Mittoo, and S. Shapera. "Anti-Neutrophil Cytoplasmic Antibody Screening in Idiopathic Interstitial Lung Disease." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3367.
Повний текст джерелаMulleman, Denis, Amina Bensalem, David Ternant, Gilles Paintaud, Divi Cornec, and Ulrich Specks. "THU0309 NONLINEAR PHARMACOKINETICS OF RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4897.
Повний текст джерелаNakagawa, Naoko, Yoshinori Tanino, Yayoi Inokoshi, Kazue Saito, Taeko Ishii, Takefumi Nikaido, Atsuro Fukuhara, et al. "Clinical Analysis Of Anti-Neutrophil Cytoplasmic Antibody In Patients With Interstitial Pneumonia." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6006.
Повний текст джерелаNakahara, M., H. Yamashita, Y. Takahashi, K. Araki, N. Mino, K. Suga, A. Yashima, and H. Kaneko. "AB0682 Risk factors associated with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5468.
Повний текст джерелаKaghazian, M., C. W. Akabusi, K. P. Acosta, K. Kallakuri, and P. Shakouri. "Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis Secondary to Pfizer-BioNTech COVID-19 Vaccine." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1384.
Повний текст джерелаBensalem, Amina, David Ternant, Nicolas Azzopardi, Gilles Paintaud, Valérie Gouilleux-Gruart, Divi Cornec, Ulrich Specks, and Denis Mulleman. "SAT0236 RELATIONSHIP BETWEEN RITUXIMAB CONCENTRATION AND AUTOANTIBODY LEVELS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7552.
Повний текст джерелаAntovic, A., M. Kostic, F. Mobarrez, A. Nordin, J. Vojinovic, A. Bruchfeld, and I. Gunnarsson. "OP0052 Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody – associated vasculitis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5465.
Повний текст джерелаShah, R., R. Trachtman, B. Coakley, and A. Vicencio. "A Rare Case of Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody Double Positive Disease in a Preschool-Aged Child." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3264.
Повний текст джерелаKobayashi, K., D. Nakagomi, S. Hanai, M. Yamagata, T. Sugiyama, H. Kawashima, M. Hiraguri, et al. "AB0676 Efficacy of rituximab therapy against anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis: a case series." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5345.
Повний текст джерела